COVID-19 vaccination: The impact on the selection criteria of the convalescent plasma donors

Transfus Clin Biol. 2021 Aug;28(3):308-309. doi: 10.1016/j.tracli.2021.05.002. Epub 2021 May 7.

Abstract

Clinical management protocols for COVID-19 are evolving rapidly as more information about the epidemiology and pathophysiological changes in COVID-19 become available. However, no definite treatment of COVID-19 has been found till date. The COVID-19 convalescent plasma (CCP) therapy has emerged as an important investigational therapy in the management of COVID-19 patients. Additionally, the regulatory agencies, in particular, the Indian blood transfusion council must release some interim recommendations for the blood centres on the CCP blood donor eligibility criteria after COVID-19 vaccination. More clinical trials are needed to know the efficacy of the CCP harvested from COVID-19 recovered individuals who have been vaccinated against those COVID-19 recovered individuals who are not vaccinated to understand the vaccine impact on the IgG titres of anti-SARS-CoV-2 antibodies.

Keywords: Blood centre; Blood donors; COVID-19; Deferral; Pandemic; Vaccine impact.

Publication types

  • Letter

MeSH terms

  • Antibodies, Viral / blood
  • Antibodies, Viral / immunology
  • Antibodies, Viral / therapeutic use*
  • Blood Safety*
  • COVID-19 / blood
  • COVID-19 / immunology
  • COVID-19 / therapy*
  • COVID-19 Serotherapy
  • COVID-19 Vaccines*
  • Donor Selection / standards*
  • Human Experimentation
  • Humans
  • Immunization, Passive / ethics
  • Immunization, Passive / standards
  • Immunoglobulin G / blood
  • Immunoglobulin G / immunology
  • Immunoglobulin G / therapeutic use*
  • Informed Consent
  • Pandemics*
  • SARS-CoV-2 / immunology*
  • Viral Proteins / immunology

Substances

  • Antibodies, Viral
  • COVID-19 Vaccines
  • Immunoglobulin G
  • Viral Proteins